Epigral Limited — Updates, 27-01-2025: Press Release

Epigral Limited reported a strong performance for Q3 FY2025, with PAT soaring 110% to ₹ 104 Crore, compared to ₹ 49 Crore in Q3 FY2024. Revenue also climbed 37% to ₹ 649 Crore, attributed to a 15% rise in sales volume from its Derivatives business. The company declared an interim dividend of 25% and invested ₹ 127 Crore in capex during the nine months of FY2025. Significant expansions include the doubling of CPVC Resin and Epichlorohydrin capacity, which will enhance future production outputs. Capacity utilization was healthy at 81%, while EBITDA grew 49% to ₹ 183 Crore, resulting in an EBITDA margin of 28%. With ROCE improving to 25% and net debt significantly reduced, Epigral is well-positioned for ongoing growth. The strategic focus on diversification and strong project execution suggests a positive outlook for the company in the coming quarters, particularly with new projects expected to contribute to revenues into FY2026.